Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Public ClinicalTrials.gov record NCT01999868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.
Study identification
- NCT ID
- NCT01999868
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Interventions
- Ustekinumab Biological
- Abatacept Biological
- UST Placebo Drug
- ABA Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2014 (Actual)
- Primary completion
- Dec 7, 2017 (Actual)
- Completion
- Mar 1, 2018 (Actual)
- Last update posted
- Jan 15, 2019
2014 – 2018
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Tulane University School of Medicine: Dept. of Dermatology | New Orleans | Louisiana | 70112 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| The Rockefeller University | New York | New York | 10065 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27104 | — |
| Case Western University | Cleveland | Ohio | 44106 | — |
| The University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01999868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2019 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01999868 live on ClinicalTrials.gov.